

Monica Gandhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5757870/publications.pdf>

Version: 2024-02-01

196
papers

7,587
citations

66343

42
h-index

76900

74
g-index

204
all docs

204
docs citations

204
times ranked

9938
citing authors

#	ARTICLE	IF	CITATIONS
1	Pragmatic randomized trial of a pre-visit intervention to improve the quality of telemedicine visits for vulnerable patients living with HIV. <i>Journal of Telemedicine and Telecare</i> , 2023, 29, 187-195.	2.7	7
2	Pilot Randomized Controlled Trial of Motivational Interviewing with Sexual Minority Male Couples to Reduce Drug Use and Sexual Risk: The Couples Health Project. <i>AIDS and Behavior</i> , 2022, 26, 310-327.	2.7	12
3	Preferences for Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence: A Discrete Choice Experiment Among Male Sex Workers in Mexico. <i>AIDS and Behavior</i> , 2022, 26, 833-842.	2.7	5
4	Examining the Impact of the Golden Compass Clinical Care Program for Older People with HIV: A Qualitative Study. <i>AIDS and Behavior</i> , 2022, 26, 1562-1571.	2.7	8
5	Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 455-462.	1.1	13
6	Equity in access to long-acting injectables in the USA. <i>Lancet HIV</i> , the, 2022, 9, e145-e147.	4.7	7
7	Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e916-e919.	5.8	42
8	Geriatric conditions and healthcare utilisation in older adults living with HIV. <i>Age and Ageing</i> , 2022, 51, .	1.6	5
9	Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e947-e954.	5.8	4
10	Brief Report: Heterogeneous Preferences for Care Engagement Among People With HIV Experiencing Homelessness or Unstable Housing During the COVID-19 Pandemic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 140-145.	2.1	4
11	Immunity Against the Omicron Variant From Vaccination, Recovery, or Both. <i>Clinical Infectious Diseases</i> , 2022, 75, e672-e674.	5.8	2
12	Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab640.	0.9	56
13	Characterizing the COVID-19 Illness Experience to Inform the Study of Post-acute Sequelae and Recovery. <i>International Journal of Behavioral Medicine</i> , 2022, 29, 610-623.	1.7	9
14	Relationship Dynamics are Associated with Self-Reported Adherence but not an Objective Adherence Measure in Malawi. <i>AIDS and Behavior</i> , 2022, 26, 3551-3562.	2.7	2
15	Distinct forms of migration and mobility are differentially associated with HIV treatment adherence. <i>Aids</i> , 2022, 36, 1021-1030.	2.2	10
16	HIV Treatment Outcomes in POP-UP: Drop-in HIV Primary Care Model for People Experiencing Homelessness. <i>Journal of Infectious Diseases</i> , 2022, 226, S353-S362.	4.0	10
17	Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. <i>AIDS Research and Therapy</i> , 2022, 19, .	1.7	1
18	Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the Latinx Population During Shelter-in-Place in San Francisco. <i>Clinical Infectious Diseases</i> , 2021, 73, S127-S135.	5.8	94

#	ARTICLE	IF	CITATIONS
19	Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection. <i>Clinical Infectious Diseases</i> , 2021, 72, 486-489.	5.8	12
20	Extent of In Utero Transfer of Tenofovir From Mother to Fetus: A Paired Analysis of Hair Specimens Collected at Birth From a Cohort in the United States. <i>Journal of Infectious Diseases</i> , 2021, 223, 638-644.	4.0	1
21	Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2021, 72, 2025-2028.	5.8	4
22	Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1169, 122467.	2.3	3
23	PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men. <i>AIDS and Behavior</i> , 2021, 25, 1299-1305.	2.7	6
24	Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach. <i>Clinical Infectious Diseases</i> , 2021, 72, 1843-1849.	5.8	15
25	A mentor training workshop focused on fostering diversity engenders lasting impact on mentoring techniques: Results of a long-term evaluation. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e116.	0.6	8
26	Uniting Infectious Disease and Physical Science Principles on the Importance of Face Masks for COVID-19. <i>Med</i> , 2021, 2, 29-32.	4.4	30
27	Diagnostic accuracy of a liquid chromatography-tandem mass spectrometry assay in small hair samples for rifampin-resistant tuberculosis drug concentrations in a routine care setting. <i>BMC Infectious Diseases</i> , 2021, 21, 99.	2.9	3
28	Masks Reduce Viral Inoculum of SARS-CoV2. <i>Journal of General Internal Medicine</i> , 2021, 36, 1124-1125.	2.6	4
29	Detectable HIV RNA in late pregnancy associated with low tenofovir hair levels at time of delivery among women living with HIV in the United States. <i>Aids</i> , 2021, 35, 267-274.	2.2	0
30	Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing. <i>Aids</i> , 2021, 35, 1241-1246.	2.2	13
31	COVID-19 Mitigation With Appropriate Safety Measures in an Essential Workplace: Lessons for Opening Work Settings in the United States During COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab086.	0.9	8
32	HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. <i>PLoS Medicine</i> , 2021, 18, e1003492.	8.4	35
33	Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 748-750.	1.1	5
34	Tenofovir-based PrEP for COVID-19: an untapped opportunity?. <i>Aids</i> , 2021, 35, 1509-1511.	2.2	9
35	HIV and women in the USA: what we know and where to go from here. <i>Lancet, The</i> , 2021, 397, 1107-1115.	13.7	35
36	Disparities in Integrase Inhibitor Usage in the Modern HIV Treatment Era: A Population-Based Study in a US City. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab139.	0.9	1

#	ARTICLE	IF	CITATIONS
37	A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1865-1873.	3.0	9
38	Point-of-Care Test for Assessing Tenofovir Adherence: Feasibility and Recommendations from Women in an Oral PrEP Program in Kenya and Their Healthcare Providers. <i>AIDS and Behavior</i> , 2021, 25, 3617-3629.	2.7	5
39	Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings. <i>Aids</i> , 2021, 35, 1439-1449.	2.2	2
40	Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. <i>Drug Testing and Analysis</i> , 2021, 13, 1354-1370.	2.6	4
41	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab200.	0.9	9
42	Drug Overdose Deaths Before and After Shelter-in-Place Orders During the COVID-19 Pandemic in San Francisco. <i>JAMA Network Open</i> , 2021, 4, e2110452.	5.9	59
43	The Drinkers™ Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial. <i>Trials</i> , 2021, 22, 355.	1.6	7
44	Adjudicating Reasons for Hospitalization Reveals That Severe Illness From COVID-19 in Children Is Rare. <i>Hospital Pediatrics</i> , 2021, 11, e159-e160.	1.3	5
45	Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. <i>Aids</i> , 2021, 35, 1919-1927.	2.2	6
46	SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. <i>Lancet HIV</i> , 2021, 8, e334-e341.	4.7	99
47	Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases – Authors' reply. <i>Lancet Infectious Diseases</i> , 2021, 21, 915-916.	9.1	2
48	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	10.3	117
49	Effectiveness of Adding a Mask Recommendation to Other Public Health Measures. <i>Annals of Internal Medicine</i> , 2021, 174, 1193-1193.	3.9	0
50	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. <i>Cell Reports</i> , 2021, 36, 109518.	6.4	142
51	High Acceptability of Donating Hair and Other Biological Samples for Research Among People Living with HIV in an Outpatient Clinic in Lagos, Nigeria. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 676-682.	1.1	2
52	COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 421-425.	2.1	29
53	Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 439-447.	2.1	4
54	Brief Report: No Difference in Urine Tenofovir Levels in Patients Living With HIV on Unboosted Versus Dose-Adjusted Boosted Tenofovir Alafenamide. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 57-60.	2.1	3

#	ARTICLE	IF	CITATIONS
55	Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e296-e301.	9.1	57
56	Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 181-185.	2.1	2
57	COVID-19 Susceptibility and Outcomes Among People Living With HIV in San Francisco. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 19-21.	2.1	51
58	Coronavirus Disease 2019 (COVID-19) and HIV Spotlight the United States Imperative for Permanent Affordable Housing. <i>Clinical Infectious Diseases</i> , 2021, 72, 2042-2043.	5.8	22
59	The impact of COVID-19 on mentoring early-career investigators. <i>Medicine (United States)</i> , 2021, 100, e27423.	1.0	5
60	Simplifying TREATment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. <i>BMJ Open</i> , 2021, 11, e050116.	1.9	7
61	Viral suppression during COVID-19 among people with HIV experiencing homelessness in a low-barrier clinic-based program. <i>Aids</i> , 2021, 35, 517-519.	2.2	19
62	Revisiting COVID-19 policies: 10 evidence-based recommendations for where to go from here. <i>BMC Public Health</i> , 2021, 21, 2084.	2.9	30
63	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). <i>Clinical Infectious Diseases</i> , 2020, 70, 2143-2151.	5.8	24
64	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. <i>Aids</i> , 2020, 34, 255-260.	2.2	38
65	HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health. <i>Aids</i> , 2020, 34, 699-706.	2.2	12
66	Moving Antiretroviral Adherence Assessments to the Modern Era: Correlations Among Three Novel Measures of Adherence. <i>AIDS and Behavior</i> , 2020, 24, 284-290.	2.7	21
67	The Golden Compass Program: Overview of the Initial Implementation of a Comprehensive Program for Older Adults Living with HIV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595822093526.	1.5	14
68	A COVID-19 conference at AIDS 2020: Virtual. <i>Lancet</i> , The, 2020, 395, 1598-1599.	13.7	4
69	Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. <i>Current HIV/AIDS Reports</i> , 2020, 17, 487-498.	3.1	19
70	Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19. <i>Aids</i> , 2020, 34, 2328-2331.	2.2	76
71	Brief Report: High Accuracy of a Real-Time Urine Antibody-Based Tenofovir Point-of-Care Test Compared With Laboratory-Based ELISA in Diverse Populations. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 149-152.	2.1	11
72	Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer. <i>Journal of General Internal Medicine</i> , 2020, 35, 3063-3066.	2.6	180

#	ARTICLE	IF	CITATIONS
73	Brief Report: Understanding Preferences for HIV Care Among Patients Experiencing Homelessness or Unstable Housing: A Discrete Choice Experiment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 444-449.	2.1	13
74	The importance of PrEP persistence in preventing HIV infections on PrEP. <i>Journal of the International AIDS Society</i> , 2020, 23, e25578.	3.0	4
75	Facial Masking for Covid-19 – Potential for “Variolation” as We Await a Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, e101.	27.0	182
76	Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 253-256.	1.3	3
77	Improving Care Outcomes for PLWH Experiencing Homelessness and Unstable Housing: a Synthetic Review of Clinic-Based Strategies. <i>Current HIV/AIDS Reports</i> , 2020, 17, 259-267.	3.1	9
78	Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. <i>International Journal of Infectious Diseases</i> , 2020, 97, 365-370.	3.3	10
79	Social Support Mitigates Negative Impact of Food Insecurity on Antiretroviral Adherence Among Postpartum Women in Western Kenya. <i>AIDS and Behavior</i> , 2020, 24, 2885-2894.	2.7	11
80	Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. <i>Lancet HIV</i> , 2020, 7, e249-e261.	4.7	94
81	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	2
82	Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 2158-2160.	27.0	976
83	Missed opportunities to prevent HIV infections among pre-exposure prophylaxis users: a population-based mixed methods study, San Francisco, United States. <i>Journal of the International AIDS Society</i> , 2020, 23, e25472.	3.0	40
84	The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa131.	0.9	17
85	Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. <i>Current HIV/AIDS Reports</i> , 2020, 17, 301-314.	3.1	83
86	Evaluation of a novel community-based COVID-19 “Test-to-Care” model for low-income populations. <i>PLoS ONE</i> , 2020, 15, e0239400.	2.5	51
87	Testing a Real-Time Tenofovir Urine Adherence Assay for Monitoring and Providing Feedback to Preexposure Prophylaxis in Kenya (PUMA): Protocol for a Pilot Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e15029.	1.0	14
88	Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	2
89	Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121729.	2.3	9
90	Feasibility and acceptability of novel methods to estimate antiretroviral adherence: A longitudinal study. <i>PLoS ONE</i> , 2019, 14, e0210791.	2.5	14

#	ARTICLE	IF	CITATIONS
91	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	1.1	8
92	Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. <i>Health and Place</i> , 2019, 57, 339-351.	3.3	38
93	Housing Instability Results in Increased Acute Care Utilization in an Urban HIV Clinic Cohort. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz148.	0.9	17
94	Willingness to Donate Hair Samples for Research Among People Living with HIV/AIDS Attending a Tertiary Health Facility in Ibadan, Nigeria. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 642-648.	1.1	7
95	Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB. <i>ERJ Open Research</i> , 2019, 5, 00046-2019.	2.6	9
96	Missed Visits Associated With Future Preexposure Prophylaxis (PrEP) Discontinuation Among PrEP Users in a Municipal Primary Care Health Network. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz101.	0.9	49
97	Addressing the Sexually Transmitted Infection and HIV Syndemic. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1356.	7.4	22
98	Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz463.	0.9	9
99	Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine. <i>Journal of the International AIDS Society</i> , 2019, 22, e25436.	3.0	49
100	Evaluating the Impact of Housing Status on Gonorrhea and Chlamydia Screening in an HIV Primary Care Setting. <i>Sexually Transmitted Diseases</i> , 2019, 46, 153-158.	1.7	9
101	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 72-77.	2.1	50
102	Measuring Adherence to Antiretroviral Therapy via Hair Concentrations in India. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 202-206.	2.1	18
103	Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 158-162.	2.1	16
104	Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. <i>Aids</i> , 2019, 33, 1657-1662.	2.2	11
105	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 78-82.	2.1	18
106	Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 149-158.	2.1	12
107	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1044-1047.	5.8	22
108	Patient and clinician perspectives on optimizing graphical displays of longitudinal medication adherence data. <i>Patient Education and Counseling</i> , 2019, 102, 1090-1097.	2.2	13

#	ARTICLE	IF	CITATIONS
109	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	4.0	73
110	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. <i>Lancet HIV</i> , 2019, 6, e43-e50.	4.7	43
111	Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. <i>Aids</i> , 2019, 33, 867-872.	2.2	29
112	Motivational Interviewing to Reduce Drug Use and HIV Incidence Among Young Men Who Have Sex With Men in Relationships and Are High Priority for Pre-Exposure Prophylaxis (Project PARTNER): Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2019, 8, e13015.	1.0	16
113	Acceptability and Feasibility of Self-Collecting Biological Specimens for HIV, Sexually Transmitted Infection, and Adherence Testing Among High-Risk Populations (Project Caboodle!): Protocol for an Exploratory Mixed-Methods Study. <i>JMIR Research Protocols</i> , 2019, 8, e13647.	1.0	13
114	Mentoring the Mentors: Implementation and Evaluation of Four Fogarty-Sponsored Mentoring Training Workshops in Low-and Middle-Income Countries. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 20-28.	1.4	24
115	Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. <i>Journal of Infectious Diseases</i> , 2018, 218, 234-238.	4.0	16
116	Seroconversion on preexposure prophylaxis. <i>Aids</i> , 2018, 32, F1-F4.	2.2	42
117	Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania. <i>Aids</i> , 2018, 32, 1115-1123.	2.2	25
118	Individual and partnership factors associated with anticipated versus actual partner notification following STI diagnosis among men who have sex with men and/or with transgender women in Lima, Peru. <i>Sexually Transmitted Infections</i> , 2018, 94, 607-610.	1.9	6
119	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 213-219.	5.8	82
120	Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value. <i>AIDS and Behavior</i> , 2018, 22, 1165-1173.	2.7	51
121	Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2018, 32, 431-441.	1.5	11
122	Degree of Housing Instability Shows Independent "Dose-Response" With Virologic Suppression Rates Among People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy035.	0.9	41
123	Loneliness in Older Adults Living with HIV. <i>AIDS and Behavior</i> , 2018, 22, 1475-1484.	2.7	82
124	Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 295-298.	2.1	23
125	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. <i>Aids</i> , 2018, 32, 2189-2194.	2.2	14
126	Brief Report: A Panel Management and Patient Navigation Intervention Is Associated With Earlier PrEP Initiation in a Safety-Net Primary Care Health System. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 347-351.	2.1	31

#	ARTICLE	IF	CITATIONS
127	2272. High Interest in Doxycycline for Sexually Transmitted Infection Post-Exposure Prophylaxis (Doxy-PEP) in a Multi-city Survey of Men Having Sex With Men (MSM) Using a Social-Networking App. <i>Open Forum Infectious Diseases</i> , 2018, 5, S672-S673.	0.9	0
128	1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report. <i>Open Forum Infectious Diseases</i> , 2018, 5, S396-S397.	0.9	2
129	Patient and provider perceptions of a comprehensive care program for HIV-positive adults over 50 years of age: The formation of the Golden Compass HIV and aging care program in San Francisco. <i>PLoS ONE</i> , 2018, 13, e0208486.	2.5	26
130	Population mobility associated with higher risk sexual behaviour in eastern African communities participating in a Universal Testing and Treatment trial. <i>Journal of the International AIDS Society</i> , 2018, 21, e25115.	3.0	33
131	Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence. <i>EClinicalMedicine</i> , 2018, 2-3, 22-28.	7.1	42
132	Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 169-174.	2.1	20
133	Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2018, 67, 962-964.	5.8	35
134	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7795-E7804.	7.1	121
135	Novel methods to estimate antiretroviral adherence: protocol for a longitudinal study. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1033-1042.	1.8	10
136	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. <i>PLoS ONE</i> , 2018, 13, e0190118.	2.5	18
137	A Simple Pre-Exposure Prophylaxis (PrEP) Optimization Intervention for Health Care Providers Prescribing PrEP: Pilot Study. <i>JMIR Formative Research</i> , 2018, 2, e2.	1.4	19
138	“The Pleasure Is Better as I’ve Gotten Older”: Sexual Health, Sexuality, and Sexual Risk Behaviors Among Older Women Living With HIV. <i>Archives of Sexual Behavior</i> , 2017, 46, 1137-1150.	1.9	38
139	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 778-783.	1.1	52
140	Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. <i>BMC Public Health</i> , 2017, 17, 383.	2.9	46
141	Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 55-59.	2.1	24
142	Predicting death over 8 years in a prospective cohort of HIV-infected women: the Women’s Interagency HIV Study. <i>BMJ Open</i> , 2017, 7, e013993.	1.9	15
143	A Pharmacist-Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV-Positive Patients. <i>Pharmacotherapy</i> , 2017, 37, 1498-1506.	2.6	73
144	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. <i>Aids</i> , 2017, 31, 2245-2251.	2.2	47

#	ARTICLE	IF	CITATIONS
145	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, e104-e106.	2.1	64
146	Brief Report: Lopinavir Hair Concentrations Are the Strongest Predictor of Viremia in HIV-Infected Asian Children and Adolescents on Second-Line Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 367-371.	2.1	19
147	Strong Correlation Between Concentrations of Antiretrovirals in Home-Collected and Study-Collected Hair Samples: Implications for Adherence Monitoring. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, e101-e103.	2.1	15
148	An LC-MS/MS-based method to analyze the anti-tuberculosis drug bedaquiline in hair. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1069-1070.	1.2	9
149	Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. <i>PLoS ONE</i> , 2017, 12, e0189101.	2.5	8
150	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-155.	0.5	63
151	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , the, 2016, 3, e521-e528.	4.7	66
152	Creating More Effective Mentors: Mentoring the Mentor. <i>AIDS and Behavior</i> , 2016, 20, 294-303.	2.7	49
153	A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 991-992.	1.2	6
154	Movement between facilities for HIV care among a mobile population in Kenya: transfer, loss to follow-up, and reengagement. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 1386-1393.	1.2	40
155	Quantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0155887.	2.5	15
156	A qualitative assessment of barriers and facilitators to antiretroviral adherence in Thai patients. <i>Journal of Virus Eradication</i> , 2016, 2, 22-7.	0.5	3
157	HIV pre-exposure prophylaxis for women. <i>Journal of Virus Eradication</i> , 2016, 2, 149-55.	0.5	33
158	Human papillomavirus knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Women's Health Study. <i>International Journal of STD and AIDS</i> , 2015, 26, 893-902.	1.1	19
159	Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women. <i>Aids</i> , 2015, 29, 825-830.	2.2	53
160	“Wan Kanyakla” (We are together): Community transformations in Kenya following a social network intervention for HIV care. <i>Social Science and Medicine</i> , 2015, 147, 332-340.	3.8	25
161	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 69, e127-e134.	2.1	41
162	Implementation challenges for long-acting antivirals as treatment. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 282-289.	3.8	33

#	ARTICLE	IF	CITATIONS
163	Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. <i>Aids</i> , 2015, 29, 183-191.	2.2	45
164	Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2015, 27, 327-332.	1.2	41
165	A mentor training program improves mentoring competency for researchers working with early-career investigators from underrepresented backgrounds. <i>Advances in Health Sciences Education</i> , 2015, 20, 683-689.	3.3	61
166	Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1009-1014.	1.1	32
167	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	4.0	62
168	Increase of perceived frequency of neighborhood domestic violence is associated with increase of women's depression symptoms in a nationally representative longitudinal study in South Africa. <i>Social Science and Medicine</i> , 2015, 131, 89-97.	3.8	17
169	Behavioral Intervention Improves Treatment Outcomes Among HIV-Infected Individuals Who Have Delayed, Declined, or Discontinued Antiretroviral Therapy: A Randomized Controlled Trial of a Novel Intervention. <i>AIDS and Behavior</i> , 2015, 19, 1801-1817.	2.7	33
170	Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 13-20.	2.1	72
171	Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0129100.	2.5	43
172	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). <i>PLoS ONE</i> , 2014, 9, e83736.	2.5	125
173	Short Communication: A Low-Cost Method for Analyzing Nevirapine Levels in Hair as a Marker of Adherence in Resource-Limited Settings. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 25-28.	1.1	41
174	Antiretroviral Concentrations in Small Hair Samples as a Feasible Marker of Adherence in Rural Kenya. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 311-315.	2.1	80
175	Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in tororo, uganda. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 121-132.	2.0	40
176	Development and Implementation of a Workshop to Enhance the Effectiveness of Mentors Working with Diverse Mentees in HIV Research. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 730-737.	1.1	28
177	Smoking Cessation and Recidivism in the Women's Interagency Human Immunodeficiency Virus Study. <i>American Journal of Preventive Medicine</i> , 2014, 47, 53-69.	3.0	33
178	Common clinical conditions " age, low BMI, ritonavir use, mild renal impairment " affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. <i>Aids</i> , 2014, 28, 59-66.	2.2	61
179	Hair and Plasma Data Show That Lopinavir, Ritonavir, and Efavirenz All Transfer From Mother to Infant In Utero, But Only Efavirenz Transfers via Breastfeeding. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 578-584.	2.1	45
180	Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. <i>Aids</i> , 2013, 27, 2413-2423.	2.2	37

#	ARTICLE	IF	CITATIONS
181	A Single-Nucleotide Polymorphism in CYP2B6 Leads to >3-Fold Increases in Efavirenz Concentrations in Plasma and Hair Among HIV-Infected Women. <i>Journal of Infectious Diseases</i> , 2012, 206, 1453-1461.	4.0	59
182	The Effect of a "Universal Antiretroviral Therapy" Recommendation on HIV RNA Levels Among HIV-Infected Patients Entering Care With a CD4 Count Greater Than 500/ÅL in a Public Health Setting. <i>Clinical Infectious Diseases</i> , 2012, 55, 1690-1697.	5.8	28
183	An Incidental Abscess in a Patient With Acquired Immunodeficiency Syndrome. <i>Infectious Diseases in Clinical Practice</i> , 2012, 20, 405-406.	0.3	1
184	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 333-339.	2.1	101
185	Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1923-1933.	3.7	36
186	Atazanavir Concentration in Hair Is the Strongest Predictor of Outcomes on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2011, 52, 1267-1275.	5.8	116
187	The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From <i>Pneumocystis jirovecii</i> Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation. <i>Clinical Infectious Diseases</i> , 2011, 53, 1008-1014.	5.8	9
188	Protease inhibitor levels in hair strongly predict virologic response to treatment. <i>Aids</i> , 2009, 23, 471-478.	2.2	92
189	Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 482-491.	2.1	22
190	Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 3401-3409.	1.5	83
191	Poverty, unstable housing, and HIV infection among women living in the United States. <i>Current HIV/AIDS Reports</i> , 2007, 4, 181-186.	3.1	92
192	Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. <i>Aids</i> , 2005, 19, 1885-1896.	2.2	79
193	SEXDIFFERENCES INPHARMACOKINETICS ANDPHARMACODYNAMICS. <i>Annual Review of Pharmacology and Toxicology</i> , 2004, 44, 499-523.	9.4	438
194	Does Patient Sex Affect Human Immunodeficiency Virus Levels?. <i>Clinical Infectious Diseases</i> , 2002, 35, 313-322.	5.8	156
195	Human herpesvirus 8, Kaposi's sarcoma, and associated conditions. <i>Clinics in Laboratory Medicine</i> , 2002, 22, 883-910.	1.4	10
196	Hair It Is: The Long and Short of Monitoring Antiretroviral Treatment. <i>Annals of Internal Medicine</i> , 2002, 137, 696.	3.9	44